Journal of Cancer Research and Clinical Oncology

, Volume 136, Issue 10, pp 1545–1556 | Cite as

Differential proteomic analysis of a highly metastatic variant of human breast cancer cells using two-dimensional differential gel electrophoresis

Original Paper


Distant metastasis represents the major lethal cause of breast cancer. To understand the molecular mechanisms of breast cancer metastasis and identify markers with metastatic potential, we established a highly metastatic variant of parental MDA-MB-231 cells (MDA-MB-231HM). Using two-dimensional electrophoresis (2-DE), we performed a proteomic comparison of the two kinds of cells. As much as 51 protein spots were differentially expressed between the selected variant and its parental counterpart in at least 3 experiments. Ten unique proteins were identified using matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry (MS), liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS), and database searching software. Among them, nine proteins were up-regulated in MDA-MB-231HM cells, including Macrophage-capping protein (CapG), Galectin-1, Chloride intracellular channel protein 1, Endoplasmic reticulum protein ERp29 precursor, Stathmin-1 (STMN1), Isoform 1 of uridine–cytidine kinase 2(UCK2), Rho GDP-dissociation inhibitor 2 (ARHGDIB), isocitrate dehydrogenase [NADP] cytoplasmic (IDH1), and N-myc downstream regulated gene 1 (NDRG1) protein. Only transgelin-2 was down-regulated. Differential expression was confirmed for three proteins including CapG, STMN1, and transgelin-2 by Western blotting analysis. Transgelin-2 was chosen for further verification by immunohistochemistry. The results suggested that 2-DE would be an efficient way to screen the proteins responsible for specific biological function. Furthermore, the findings imply that different proteins may be involved in the metastatic process in breast carcinomas.


Breast cancer Metastasis Two-dimensional gel electrophoresis Mass spectrometry 

Supplementary material

432_2010_812_MOESM1_ESM.ppt (379 kb)
Supplementary figure 1 Representative protein spot 1(CapG) was up-regulated in MDA-MB-231 HM cells, which can be repeated in at least 3 experiments (PPT 379 kb)
432_2010_812_MOESM2_ESM.ppt (394 kb)
Supplementary figure 2 Representative protein spot 4(ERp29) was up-regulated in MDA-MB-231 HM cells, which can be repeated in at least 3 experiments (PPT 394 kb)
432_2010_812_MOESM3_ESM.ppt (566 kb)
Supplementary figure 3 Representative protein spot 6(STMN1) was up-regulated in MDA-MB-231 HM cells, which can be repeated in at least 3 experiments (PPT 567 kb)


  1. Ahn J, Murphy M, Kratowicz S, Wang A, Levine AJ, George DL (1999) Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction. Oncogene 18:5954–5958CrossRefPubMedGoogle Scholar
  2. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN (1987) A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47:3239–3245PubMedGoogle Scholar
  3. Baldassarre G, Belletti B, Nicoloso MS, Schiappacassi M, Vecchione A, Spessotto P, Morrione A, Canzonieri V, Colombatti A (2005) p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell 7:51–63CrossRefPubMedGoogle Scholar
  4. Belmont LD, Mitchison TJ (1996) Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Cell 84:623–631CrossRefPubMedGoogle Scholar
  5. Blackstock WP, Weir MP (1999) Proteomics: quantitative and physical mapping of cellular proteins. Trends Biotechnol 17:121–127CrossRefPubMedGoogle Scholar
  6. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254CrossRefPubMedGoogle Scholar
  7. Brattsand G, Roos G, Marklund U, Ueda H, Landberg G, Nånberg E, Sideras P, Gullberg M (1993) Quantitative analysis of the expression and regulation of an activation-regulated phosphoprotein (oncoprotein 18) in normal and neoplastic cells. Leukemia 7:569–579PubMedGoogle Scholar
  8. Budde PP, Kumagai A, Dunphy WG, Heald R (2001) Regulation of Op18 during spindle assembly in Xenopus egg extracts. J Cell Biol 153:149–158CrossRefPubMedGoogle Scholar
  9. Cangul H (2004) Hypoxia upregulates the expression of the NDRG1 gene leading to its overexpression in various human cancers. BMC Genet 5:27CrossRefPubMedGoogle Scholar
  10. Cangul H, Salnikow K, Yee H, Zagzag D, Commes T, Costa M (2002) Enhanced overexpression of an HIF-1/hypoxia-related protein in cancer cells. Environ Health Perspect 110:783–788PubMedGoogle Scholar
  11. Christgen M, Lehmann U (2007) MDA-MB-435: the questionable use of a melanoma cell line as a model for human breast cancer is ongoing. Cancer Biol Ther 6:1355–1357CrossRefPubMedGoogle Scholar
  12. Curmi PA, Noguès C, Lachkar S, Carelle N, Gonthier MP, Sobel A, Lidereau R, Bièche I (2000) Overexpression of stathmin in breast carcinomas points out to highly proliferative tumours. Br J Cancer 82:142–150CrossRefPubMedGoogle Scholar
  13. Dahl E, Sadr-Nabavi A, Klopocki E, Betz B, Grube S, Kreutzfeld R, Himmelfarb M, An HX, Gelling S, Klaman I, Hinzmann B, Kristiansen G, Grützmann R, Kuner R, Petschke B, Rhiem K, Wiechen K, Sers C, Wiestler O, Schneider A, Höfler H, Nährig J, Dietel M, Schäfer R, Rosenthal A, Schmutzler R, Dürst M, Meindl A, Niederacher D (2005) Systematic identification and molecular characterization of genes differentially expressed in breast and ovarian cancer. J Pathol 205:21–28CrossRefPubMedGoogle Scholar
  14. Ding SJ, Li Y, Tan YX, Jiang MR, Tian B, Liu YK, Shao XX, Ye SL, Wu JR, Zeng R, Wang HY, Tang ZY, Xia QC (2004) From proteomic analysis to clinical significance: overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis. Mol Cell Proteomics 3:73–81PubMedGoogle Scholar
  15. Ellen TP, Ke Q, Zhang P, Costa M (2008) NDRG1, a growth and cancer related gene: regulation of gene expression and function in normal and disease states. Carcinogenesis 29:2–8CrossRefPubMedGoogle Scholar
  16. Ellison G, Klinowska T, Westwood RF, Docter E, French T, Fox JC (2002) Further evidence to support the melanocytic origin of MDA-MB-435. Mol Pathol 55:294–299CrossRefPubMedGoogle Scholar
  17. Feng JT, Liu YK, Song HY, Dai Z, Qin LX, Almofti MR, Fang CY, Lu HJ, Yang PY, Tang ZY (2005) Heat-shock protein 27: a potential biomarker for hepatocellular carcinoma identified by serum proteome analysis. Proteomics 5:4581–4588CrossRefPubMedGoogle Scholar
  18. Fisher B, Dignam J, Bryant J, Wolmark N (2001) Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93:684–690CrossRefPubMedGoogle Scholar
  19. Gildea JJ, Seraj MJ, Oxford G, Harding MA, Hampton GM, Moskaluk CA, Frierson HF, Conaway MR, Theodorescu D (2002) RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res 62:6418–6423PubMedGoogle Scholar
  20. Hou YF, Yuan ST, Li HC, Wu J, Lu JS, Liu G, Lu LJ, Shen ZZ, Ding J, Shao ZM (2004) ERbeta exerts multiple stimulative effects on human breast carcinoma cells. Oncogene 23:5799–5806CrossRefPubMedGoogle Scholar
  21. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS, ATAC Trialists’ Group (2005) Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62CrossRefPubMedGoogle Scholar
  22. Hurst DR, Xie Y, Vaidya KS, Mehta A, Moore BP, Accavitti-Loper MA, Samant RS, Saxena R, Silveira AC, Welch DR (2008) Alterations of BRMS1–ARID4A interaction modify gene expression but still suppress metastasis in human breast cancer cells. J Biol Chem 283:7438–7444CrossRefPubMedGoogle Scholar
  23. Keller A, Nesvizhskii AI, Kolker E, Aebersold R (2002) Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 74:5383–5392CrossRefPubMedGoogle Scholar
  24. Kurdistani SK, Arizti P, Reimer CL, Sugrue MM, Aaronson SA, Lee SW (1998) Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage. Cancer Res 58:4439–4444PubMedGoogle Scholar
  25. Lachat P, Shaw P, Gebhard S, van Belzen N, Chaubert P, Bosman FT (2002) Expression of NDRG1, a differentiation-related gene, in human tissues. Histochem Cell Biol 118:399–408CrossRefPubMedGoogle Scholar
  26. Lal A, Lash AE, Altschul SF, Velculescu V, Zhang L, McLendon RE, Marra MA, Prange C, Morin PJ, Polyak K, Papadopoulos N, Vogelstein B, Kinzler KW, Strausberg RL, Riggins GJ (1999) A public database for gene expression in human cancers. Cancer Res 59:5403–5407PubMedGoogle Scholar
  27. Li DQ, Wang L, Fei F, Hou YF, Luo JM, Wei-Chen, Zeng R, Wu J, Lu JS, Di GH, Ou ZL, Xia QC, Shen ZZ, Shao ZM (2006) Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatography-ion trap-mass spectrometry. Proteomics 6:3352–3368CrossRefPubMedGoogle Scholar
  28. Li M, Li S, Lou Z, Liao X, Zhao X, Meng Z, Bartlam M, Rao Z (2008) Crystal structure of human transgelin. J Struct Biol 162:229–236CrossRefPubMedGoogle Scholar
  29. Liu YF, Xiao ZQ, Li MX, Li MY, Zhang PF, Li C, Li F, Chen YH, Yi H, Yao HX, Chen ZC (2009) Quantitative proteome analysis reveals annexin A3 as a novel biomarker in lung adenocarcinoma. J Pathol 217:54–64CrossRefPubMedGoogle Scholar
  30. Luo XN, Mookerjee B, Ferrari A, Mistry S, Atweh GF (1994) Regulation of phosphoprotein p18 in leukemic cells. Cell cycle regulated phosphorylation by p34cdc2 kinase. J Biol Chem 269:10312–10318PubMedGoogle Scholar
  31. Nair RR, Solway J, Boyd DD (2006) Expression cloning identifies transgelin (SM22) as a novel repressor of 92-kDa type IV collagenase (MMP-9) expression. J Biol Chem 281:26424–26436CrossRefPubMedGoogle Scholar
  32. Nesvizhskii AI, Keller A, Kolker E, Aebersold R (2003) A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 75:4646–4658CrossRefPubMedGoogle Scholar
  33. Nishio S, Ushijima K, Tsuda N, Takemoto S, Kawano K, Yamaguchi T, Nishida N, Kakuma T, Tsuda H, Kasamatsu T, Sasajima Y, Kage M, Kuwano M, Kamura T (2008) Cap43/NDRG1/Drg-1 is a molecular target for angiogenesis and a prognostic indicator in cervical adenocarcinoma. Cancer Lett 264:36–43CrossRefPubMedGoogle Scholar
  34. Nylander K, Marklund U, Brattsand G, Gullberg M, Roos G (1995) Immunohistochemical detection of oncoprotein 18 (Op18) in malignant lymphomas. Histochem J 27:155–160CrossRefPubMedGoogle Scholar
  35. Onoda K, Yu FX, Yin HL (1993) gCap39 is a nuclear and cytoplasmic protein. Cell Motil Cytoskelet 26:227–238CrossRefGoogle Scholar
  36. Pollard TD, Borisy GG (2003) Cellular motility driven by assembly and disassembly of actin filaments. Cell 112:453–465CrossRefPubMedGoogle Scholar
  37. Price DK, Ball JR, Bahrani-Mostafavi Z, Vachris JC, Kaufman JS, Naumann RW, Higgins RV, Hall JB (2000) The phosphoprotein Op18/stathmin is differentially expressed in ovarian cancer. Cancer Invest 18:722–730CrossRefPubMedGoogle Scholar
  38. Rae JM, Ramus SJ, Waltham M, Armes JE, Campbell IG, Clarke R, Barndt RJ, Johnson MD, Thompson EW (2004) Common origins of MDA-MB-435 cells from various sources with those shown to have melanoma properties. Clin Exp Metastasis 21:543–552CrossRefPubMedGoogle Scholar
  39. Rae JM, Creighton CJ, Meck JM, Haddad BR, Johnson MD (2007) MDA-MB-435 cells are derived from M14 melanoma cells–a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 104:13–19CrossRefPubMedGoogle Scholar
  40. Rana S, Maples PB, Senzer N, Nemunaitis J (2008) Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther 8:1461–1470CrossRefPubMedGoogle Scholar
  41. Renz M, Betz B, Niederacher D, Bender HG, Langowski J (2008) Invasive breast cancer cells exhibit increased mobility of the actin-binding protein CapG. Int J Cancer 122:1476–1482CrossRefPubMedGoogle Scholar
  42. Rowlands DC, Williams A, Jones NA, Guest SS, Reynolds GM, Barber PC, Brown G (1995) Stathmin expression is a feature of proliferating cells of most, if not all, cell lineages. Lab Invest 72:100–113PubMedGoogle Scholar
  43. Schunke D, Span P, Ronneburg H, Dittmer A, Vetter M, Holzhausen HJ, Kantelhardt E, Krenkel S, Müller V, Sweep FC, Thomssen C, Dittmer J (2007) Cyclooxygenase-2 is a target gene of rho GDP dissociation inhibitor beta in breast cancer cells. Cancer Res 67:10694–10702CrossRefPubMedGoogle Scholar
  44. Shevchenko A, Wilm M, Vorm O, Mann M (1996) Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 68:850–858CrossRefPubMedGoogle Scholar
  45. Thompson CC, Ashcroft FJ, Patel S, Saraga G, Vimalachandran D, Prime W, Campbell F, Dodson A, Jenkins RE, Lemoine NR, Crnogorac-Jurcevic T, Yin HL, Costello E (2007) Pancreatic cancer cells overexpress gelsolin family-capping proteins, which contribute to their cell motility. Gut 56:95–106CrossRefPubMedGoogle Scholar
  46. Van Belzen N, Dinjens WN, Diesveld MP, Groen NA, van der Made AC, Nozawa Y, Vlietstra R, Trapman J, Bosman FT (1997) A novel gene which is up-regulated during colon epithelial cell differentiation and down-regulated in colorectal neoplasms. Lab Invest 77:85–92PubMedGoogle Scholar
  47. Van Ginkel PR, Gee RL, Walker TM, Hu DN, Heizmann CW, Polans AS (1998) The identification and differential expression of calcium-binding proteins associated with ocular melanoma. Biochim Biophys Acta 1448:290–297CrossRefPubMedGoogle Scholar
  48. Weigelt B, Peterse JL, van ‘t Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5:591–602CrossRefPubMedGoogle Scholar
  49. Yan JX, Wait R, Berkelman T, Harry RA, Westbrook JA, Wheeler CH, Dunn MJ (2000) A modified silver staining protocol for visualization of proteins compatible with matrix-assisted laser desorption/ionization and electrospray ionization-mass spectrometry. Electrophoresis 21:3666–3672CrossRefPubMedGoogle Scholar
  50. Yang Z, Chang YJ, Miyamoto H, Ni J, Niu Y, Chen Z, Chen YL, Yao JL, di Sant’Agnese PA, Chang C (2007) Transgelin functions as a suppressor via inhibition of ARA54-enhanced androgen receptor transactivation and prostate cancer cell growth. Mol Endocrinol 21:343–358CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Department of Oncology, Breast Cancer Institute, Cancer Hospital/Cancer Institute, Institutes of Biomedical Science, Shanghai Medical CollegeFudan UniversityShanghaiPeople’s Republic of China

Personalised recommendations